A Phase 3 interventional study of sacubitril/valsartan in Heart Failure, sponsored by Novartis Pharmaceuticals. Completed at 79 sites in 27 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing sacubitril in Heart Failure — 5 open to participants now, 5 under way, 2 of them phase 3. sacubitril · Heart Failure.
Among the 24 studies testing sacubitril in Heart Failure, this one is the 9th largest by enrollment, is one of 4 that started in 2019, is one of 7 in phase 3, and was the 9th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →5 of the 24 studies testing sacubitril in Heart Failure are open now, in 5 countries. Recruiting first, the newest first:
Martin Rohacek · Sites in Tanzania
Ages 18+
Kafrelsheikh University · Sites in Egypt
Ages 18+
John Paul II Hospital, Krakow · Sites in Poland
Ages 18+
Heart Center Research, LLC · Sites in United States
Ages 19+
Puerta de Hierro University Hospital · Sites in Spain
Ages 18+
By country, each count listing its studies:
sacubitril: first FDA approval 2015 (ENTRESTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 216 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 104 across the 24 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
74 studies in Heart Failure by Novartis: 4 open now, 4 under way, 2 of them phase 3. Of 68 finished, 38 (56%) have results posted.
Among the 74 studies in Heart Failure by Novartis, this one is the 27th largest by enrollment of the 54 interventional ones that give a count, is one of 5 that started in 2019, is one of 21 in phase 3, and was the 46th registered.
Novartis’s Heart Failure studies by the year they started, since 2002.
1 of the studies testing sacubitril in Heart Failure that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712030Phase 3Puerta de Hierro University HospitalEffect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing sacubitril in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 74 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate long-term safety and tolerability and to provide post-trial access to sacubitril/valsartan to eligible participants who successfully completed CLCZ696B2319 (PANORAMA-HF) core study Part 2 as per protocol.
This was a multicenter, open-label long-term extension study for participants who successfully completed PANORAMA-HF core study Part 2 of the trial or who discontinued study drug treatment early in Part 2 due to the implementation of Urgent safety measure (USM) of PANORAMA-HF core study. Provided that they fulfilled the protocol requirements, these patients were eligible to participate in the OLE. Depending on when and where the participant was enrolled, the duration of the study was of a minimum of 1 year, or until receipt of local marketing authorization and commercial availability, or reaching the maximum limit allowed by local regulations, or until Dec-2023, whichever occurred first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single arm, open label sacubitril/valsartan
Drug: sacubitril/valsartan
Drug pages: Sacubitril · Valsartan
Target dose 3.1 mg/kg bid Formulations: Tablets (50, 100, 200 mg) Granules \[12.5 mg (4 granules), 31.25 mg (10 granules), in capsules\] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)
Also known as: LCZ696
Number of Participants With Adverse Events
Number of participants with at least one Adverse Events (AEs)
Time frame: to end of study, up to 4,5 years
Number of Participants With Serious Adverse Events
Number of participants with at least one Serious Adverse Events (SAEs)
Time frame: to end of study, up to 4.5 years
Duration of Drug Exposure
Median duration of exposure to sacubitril/valsartan (including temporary interruptions)
Time frame: Up to 4.5 years
79 centers in 27 countries: Korea, Republic of(4), United States(15), Bulgaria(1), Italy(7), Thailand(2), Poland(2), Japan(8), Singapore(2), Israel(1), Turkey(3), Taiwan(2), South Africa(1), Portugal(3), Lebanon(2), Canada(2), Switzerland(1), Czech Republic(1), Croatia(1), Argentina(1), Hungary(1), India(4), Germany(5), France(1), Austria(1), Spain(5), Russia(2), Finland(1)
| Milestone | Age Group 1 | Age Group 2 |
|---|---|---|
| Started | 130 | 86 |
| Safety set (saf) | 130 | 85 |
| Completed | 92 | 74 |
| Not completed | 38 | 12 |
| Withdrew: Adverse event | 16 | 1 |
| Withdrew: Death | 6 | 4 |
| Withdrew: Guardian decision | 4 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 8 | 5 |
| Withdrew: Participant decision | 2 | 0 |
| Withdrew: Other | 1 | 0 |
| Withdrew: No treatment was received | 0 | 1 |
Number of participants with at least one Adverse Events (AEs)
| Participants | Age Group 1 | Age Group 2 |
|---|---|---|
| Number of Participants With Adverse Events | 111 | 78 |
Number of participants with at least one Serious Adverse Events (SAEs)
| Participants | Age Group 1 | Age Group 2 |
|---|---|---|
| Number of Participants With Serious Adverse Events | 59 | 25 |
Median duration of exposure to sacubitril/valsartan (including temporary interruptions)
| Days | Age Group 1 | Age Group 2 |
|---|---|---|
| Duration of Drug Exposure | 894 (23 to 1612) | 951 (62 to 1570) |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 4.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Age Group 1 | 7/130 (5.4%) | 59/130 (45.4%) | 90/130 (69.2%) |
| Age Group 2 | 4/85 (4.7%) | 25/85 (29.4%) | 60/85 (70.6%) |
| Total | 11/215 (5.1%) | 84/215 (39.1%) | 150/215 (69.8%) |
| Event | Age Group 1 | Age Group 2 | Total |
|---|---|---|---|
| Cardiac failureCardiac disorders | 15/130 | 3/85 | 18/215 |
| COVID-19Infections and infestations | 4/130 | 4/85 | 8/215 |
| PneumoniaInfections and infestations | 5/130 | 4/85 | 9/215 |
| Dilated cardiomyopathyCardiac disorders | 5/130 | 0/85 | 5/215 |
| Chest painGeneral disorders | 5/130 | 0/85 | 5/215 |
| PyrexiaGeneral disorders | 3/130 | 3/85 | 6/215 |
| Cardiac failure chronicCardiac disorders | 4/130 | 2/85 | 6/215 |
| GastroenteritisInfections and infestations | 4/130 | 2/85 | 6/215 |
| Cardiac failure acuteCardiac disorders | 2/130 | 2/85 | 4/215 |
| VomitingGastrointestinal disorders | 3/130 | 2/85 | 5/215 |
| Event | Age Group 1 | Age Group 2 | Total |
|---|---|---|---|
| COVID-19Infections and infestations | 23/130 | 24/85 | 47/215 |
| PyrexiaGeneral disorders | 15/130 | 22/85 | 37/215 |
| Upper respiratory tract infectionInfections and infestations | 8/130 | 22/85 | 30/215 |
| CoughRespiratory, thoracic and mediastinal disorders | 20/130 | 19/85 | 39/215 |
| NasopharyngitisInfections and infestations | 12/130 | 14/85 | 26/215 |
| VomitingGastrointestinal disorders | 15/130 | 12/85 | 27/215 |
| HypotensionVascular disorders | 18/130 | 3/85 | 21/215 |
| HeadacheNervous system disorders | 15/130 | 3/85 | 18/215 |
| DizzinessNervous system disorders | 14/130 | 0/85 | 14/215 |
| DiarrhoeaGastrointestinal disorders | 9/130 | 9/85 | 18/215 |
Baseline Participants are based on the Safety Set (SAF) population, as primary analysis are based on the SAF.
| Age, Continuous(Years) | Age Group 1 | Age Group 2 | Total |
|---|---|---|---|
| Mean | 12.83 ± 3.864 | 2.94 ± 1.149 | 8.92 ± 5.747 |
| Sex: Female, Male(Participants) | Age Group 1 | Age Group 2 | Total |
|---|---|---|---|
| Female | 60 | 49 | 109 |
| Male | 70 | 36 | 106 |
| Race/Ethnicity, Customized(Participants) | Age Group 1 | Age Group 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| White | 78 | 41 | 119 |
| Asian | 24 | 23 | 47 |
| Black or African American | 19 | 10 | 29 |
| Multiple | 0 | 4 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Unknown | 7 | 6 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from May 2019 to primary completion in Dec 2023, 55 months.
Results were first posted in Jul 2024, 6 months after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 55 months is above that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sacubitril · Valsartan